Skip to main content
Caplight Logo









Fermelanta, Inc.

Fermelanta, Inc.

Private
NonoichiHealthcare & Life Scienceshttps://fermelanta.com/

Last Round

Series A

Aug 28, 2025

Total Funding Raised

$15.3M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Fermelanta, Inc. is a biotechnology company that develops plant secondary metabolites using a microbial fermentation process for industrial raw materials and ingredients including medicines, cosmetics, or supplements.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clean Manufacturing, Sustainable Materials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

synthetic biologyprecision fermentationmicrobial fermentationbio-manufacturingstrain engineeringCDMOcontract development and manufacturingbioactive ingredientssynbiometabolic engineeringbiotech startupnatural compound productionfermentation scale-upsustainable chemicalscell factory

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Fermelanta, Inc. Comparables

Compare Fermelanta, Inc. with similar companies based on industry and business-model similarity.

Fermelanta, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Conagen
83%
Antheia
76%
Manus Bio
76%

Fermelanta, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 28, 2025
SeedJun 13, 2023

Key People

Founding team and executive leadership

Shogo Fukizaki

Co-Founder CEO

Founding Team

Akira Nakagawa

Chief Technology Officer

Executive Team

Fermelanta, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2027

    Construction of a commercial-scale mass-production plant to begin in early 2027.

  • Jul 24, 2026

    Monthly visitors increased 49% MoM.

Fermelanta, Inc. Filings

Explore SEC and related filing metadata, where available.

Fermelanta, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Fermelanta, Inc.'s valuation, stock price, and market status.

Is Fermelanta, Inc. a public or private company?

Fermelanta, Inc. is a private company.

What is the current stock price of Fermelanta, Inc.?

Fermelanta, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Fermelanta, Inc. worth (valuation)?

Valuation information for Fermelanta, Inc. is not publicly available.

Can I buy Fermelanta, Inc. stock?

Fermelanta, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Fermelanta, Inc.'s last funding round?

Fermelanta, Inc.'s most recent funding round was Series A on August 28, 2025.

Who are the main investors in Fermelanta, Inc.?

Key investors in Fermelanta, Inc. include Universal Materials Incubator, Beyond Next Ventures.

Will Fermelanta, Inc. IPO soon?

No public IPO plans have been announced for Fermelanta, Inc..

How can I track Fermelanta, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Fermelanta, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNonoichi
Employee Range16
Year Founded2022
Last FundingAug 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?